Print Page     Close Window     

2019 Press Releases

Keyword Search
 
2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012
DateTitle 
February 14, 2019BioTime Provides Business Update Including Information on AgeX, OncoCyte and Asterias
ALAMEDA, Calif., Feb. 14, 2019 (GLOBE NEWSWIRE) -- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today provided a business update which included information on AgeX Therapeutics, Inc. (AgeX) (NYSE American: AGE) and BioTime’s two affiliated companies, OncoCyte Corporation (OncoCyte) (NYSE American: OCX), and Asterias Biotherapeutics, Inc. (Asterias) (NYSE American: AST). “In the past five months, BioTime has made rapid progress ... 
Printer Friendly Version
January 30, 2019BioTime Inc. Affiliate Company OncoCyte Corporation Reports Successful Results With DetermaVu™ Diagnostic Test for Lung Cancer
ALAMEDA, Calif., Jan. 30, 2019 (GLOBE NEWSWIRE) -- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that its affiliate company, OncoCyte Corporation (OncoCyte) (OCX), a developer of novel, non-invasive tests for the early detection of cancer, has reported positive results from an R&D validation study of DetermaVu™, a non-invasive, liquid biopsy test intended to facilitate clinical decision making in lung cancer dia... 
Printer Friendly Version
January 07, 2019BioTime Enters Into Exclusive Agreement With Orbit Biomedical Ltd. to Access Innovative Device for the Sub-Retinal Delivery of OpRegen® Cells for the Treatment of Dry-AMD
ALAMEDA, Calif., Jan. 07, 2019 (GLOBE NEWSWIRE) -- BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that it has entered into a research and option agreement with Orbit Biomedical Limited (“Orbit Biomedical”).  Orbit Biomedical, based in London, UK and Ambler, PA, was founded in 2018 to develop a surgical device and training platform for the delivery of cell and gene therapies to the sub-retinal space.  Under t... 
Printer Friendly Version
January 04, 2019BioTime Announces Management Changes Concurrent With Participation at 2019 J.P. Morgan Healthcare Conference and 2019 Biotech Showcase
ALAMEDA, Calif., Jan. 04, 2019 (GLOBE NEWSWIRE) -- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced the appointment of Brandi L. Roberts, M.B.A. as Chief Financial Officer and Senior Vice President, Finance, effective January 7, 2019. Ms. Roberts brings more than 23 years of public accounting and finance experience, including 20 years at publicly traded pharmaceutical, medical technology, and life science companies.  M... 
Printer Friendly Version
January 02, 2019BioTime to Present at 2019 Biotech Showcase Investor Conference on January 7, 2019
ALAMEDA, Calif.--(BUSINESS WIRE)--Jan. 2, 2019-- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that Brian M. Culley, Chief Executive Officer of BioTime will be presenting at the 2019 Biotech Showcase Investor Conference on January 7th, 2019 at 9am Pacific Time at the Hilton San Francisco Union Square Hotel in the Franciscan A Ballroom in San Francisco, CA. ... 
Printer Friendly Version

© Copyright BioTime, Inc.